Ajanta Pharma Q3 FY26: revenue rises 20%, PAT up 18%
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma reported Q3 FY26 consolidated revenue of Rs 1,375 cr, up 20% YoY. EBITDA rose 19% to Rs 382 cr with margin steady at 28%. PAT grew 18% to Rs 274 cr. For 9M FY26, revenue rose 16% to Rs 4,031 cr and PAT grew 14% to Rs 789 cr. US generics surged 52% in Q3, India branded grew 19%. Africa institution business declined due to lower aid agency procurement. Income tax search at company premises in August 2025 flagged by auditor as emphasis of matter with no financial impact quantified yet. Auditor B S R & Co. LLP gave an unmodified opinion.
Strong Q3 with 20% revenue growth and 28% margin held. US business is accelerating. Tax search overhang noted but no immediate financial impact.